Autolus Therapeutics plc: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...
ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing ...
MarketWatch17h
Crude Oil WTI (NYM $/bbl) Front Month
2-Year U.S. Treasury Note Continuous Contract $103.508 0.020 0.02% 5-Year U.S. Treasury Note Continuous Contract $107.969 0.047 0.04% 10-Year U.S. Treasury Note Continuous Contract $111.125 0.125 ...